Replies to post #5672 on AEterna Zentaris Inc. (AEZS)

[~ Blue ~]

Their accomplishment of isolating the first milligram of pure thyrotropin-releasing hormone, Guillemin stated, cost many times more than the NASA space mission that brought a kilogram of moon rock back to earth.

Read more: http://www.faqs.org/health/bios/19/Andrew-V-Schally.html#ixzz3kKqfuAl4

[tob999]

Impressive!

Andrzej Viktor "Andrew" Schally (born November 30, 1926) is a Polish-American endocrinologist and Nobel Prize laureate (1977) in medicine, sharing the prize that year with Roger Guillemin and Rosalyn Sussman Yalow.

[~ Blue ~]

THE BEST NEWS ATTRACTED ME TO THIS STOCK! http://investorshub.advfn.com/boards/read_msg.aspx?message_id=116615381

[chmcnfunds]

Incorrect and outdated information in this Sticky:

"4) AEZS~ huge success in Prostate Cancer trial!"

They have suspended the Phase 2 study of this. So the results must not have been that spectacular. Maybe good drug, but not proven useful to AEZS:

_____________________________________________________

Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
This study has suspended participant recruitment.
(Drug shortage)
Sponsor:
University of Southern California
Collaborators:
National Cancer Institute (NCI)
AEterna Zentaris
Information provided by (Responsible Party):
University of Southern California
ClinicalTrials.gov Identifier:
NCT01240629
First received: June 30, 2010
Last updated: May 21, 2015
Last verified: May 2015
History of Changes

https://clinicaltrials.gov/ct2/show/NCT01240629?term=AEZS&rank=4

_______________________________________________

"Drug shortage" ???

Can't produce drug for trials and yet they are going to market and manufacture?

RED FLAG

AEZS